Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Argus Health
Citi
Cipla
Medtronic
Cantor Fitzgerald

Generated: September 19, 2019

DrugPatentWatch Database Preview

Patent: 9,925,180

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,925,180
Title:Compounds and anti-tumor NQO1 substrates
Abstract: Compositions comprising Formula (I) can be selectively lethal toward a variety of different cancer cell types. The compositions are useful for the management, treatment, control, or adjunct treatment of diseases, where the selective lethality is beneficial in chemotherapeutic therapy.
Inventor(s): Hergenrother; Paul J. (Champaign, IL), Boothman; David A. (Dallas, TX), Bair; Joseph S. (Albany, CA), Palchaudhuri; Rahul (Cambridge, MA), Parkinson; Elizabeth I. (Champaign, IL)
Assignee: The Board of Trustees of the University of Illinois (Urbana, IL) The Board of Regents of the University of Texas System (Austin, TX)
Application Number:15/454,377
Patent Claims:see list of patent claims

Details for Patent 9,925,180

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Merck ELSPAR asparaginase VIAL 101063 001 1978-01-10 ➤ Sign Up The Board of Trustees of the University of Illinois (Urbana, IL) The Board of Regents of the University of Texas System (Austin, TX) 2031-10-14 RX search
Genentech RITUXAN rituximab VIAL 103705 001 1997-11-26 ➤ Sign Up The Board of Trustees of the University of Illinois (Urbana, IL) The Board of Regents of the University of Texas System (Austin, TX) 2031-10-14 RX search
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25 ➤ Sign Up The Board of Trustees of the University of Illinois (Urbana, IL) The Board of Regents of the University of Texas System (Austin, TX) 2031-10-14 RX Orphan search
Genzyme CAMPATH alemtuzumab VIAL; INTRAVENOUS 103948 001 2001-05-07 ➤ Sign Up The Board of Trustees of the University of Illinois (Urbana, IL) The Board of Regents of the University of Texas System (Austin, TX) 2031-10-14 RX Orphan search
Genzyme CAMPATH alemtuzumab VIAL; INTRAVENOUS 103948 002 2001-05-07 ➤ Sign Up The Board of Trustees of the University of Illinois (Urbana, IL) The Board of Regents of the University of Texas System (Austin, TX) 2031-10-14 RX Orphan search
Genzyme LEMTRADA alemtuzumab INJECTABLE;INJECTION 103948 003 2001-05-07 ➤ Sign Up The Board of Trustees of the University of Illinois (Urbana, IL) The Board of Regents of the University of Texas System (Austin, TX) 2031-10-14 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Accenture
Daiichi Sankyo
QuintilesIMS
Argus Health
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.